These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11579112)

  • 1. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
    Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
    J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The radioisotope contributes significantly to the activity of radioimmunotherapy.
    Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
    Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
    Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
    J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
    Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
    J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
    Zelenetz AD
    Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
    Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
    J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
    Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
    J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with non-Hodgkin's lymphoma treated with Bexxar with or without external-beam radiotherapy.
    Smith K; Byer G; Morris CG; Kirwan JM; Lightsey J; Mendenhall NP; Hoppe BS; Lynch J; Olivier K
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1122-7. PubMed ID: 21570217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
    Vose JM
    Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of 131I-tositumomab.
    Lewington V
    Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
    Horning SJ; Younes A; Jain V; Kroll S; Lucas J; Podoloff D; Goris M
    J Clin Oncol; 2005 Feb; 23(4):712-9. PubMed ID: 15613695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
    Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
    J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
    Dosik AD; Coleman M; Kostakoglu L; Furman RR; Fiore JM; Muss D; Niesvizky R; Shore T; Schuster MW; Stewart P; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Cancer; 2006 Feb; 106(3):616-22. PubMed ID: 16362977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
    Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
    Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
    J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
    Leonard JP; Coleman M; Kostakoglu L; Chadburn A; Cesarman E; Furman RR; Schuster MW; Niesvizky R; Muss D; Fiore J; Kroll S; Tidmarsh G; Vallabhajosula S; Goldsmith SJ
    J Clin Oncol; 2005 Aug; 23(24):5696-704. PubMed ID: 16110029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas.
    Capizzi RL
    Trans Am Clin Climatol Assoc; 2004; 115():255-72. PubMed ID: 17060972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
    Wahl RL; Zasadny KR; MacFarlane D; Francis IR; Ross CW; Estes J; Fisher S; Regan D; Kroll S; Kaminski MS
    J Nucl Med; 1998 Aug; 39(8 Suppl):21S-27S. PubMed ID: 9708567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.